KB 103

Drug Profile

KB 103

Alternative Names: KB103

Latest Information Update: 17 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Krystal Biotech
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Epidermolysis bullosa
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Epidermolysis bullosa

Most Recent Events

  • 13 Nov 2017 Recombinant DNA Advisory Committee grants clearance for phase I/II trial of KB 103 in Epidermolysis bullosa
  • 07 Nov 2017 KB 103 receives Orphan Drug status for Epidermolysis bullosa in USA
  • 03 Nov 2017 Krystal Biotech announces intention to submit IND application for Epidermolysis bullosa with the US FDA in Q1 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top